

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



中生北控生物科技股份有限公司
BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 8247)

ANNOUNCEMENT

(1) INSIDE INFORMATION; AND
(2) RE-DESIGNATION OF A DIRECTOR

(1) INSIDE INFORMATION

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Biosino Bio-Technology and Science Incorporation (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 17.10(2) of the Rules Governing the Listing of Securities on GEM (the “**GEM Listing Rules**”) of The Stock Exchange of Hong Kong Limited and the Inside Information Provisions (as defined in the GEM Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”).

The Board has been informed that, Mr. Wu Lebin (吳樂斌) (“**Mr. Wu**”), the Chairman of the Board and an executive Director of the Company, and Mr. Chen Peng (陳鵬), the President and an executive Director of the Company, are currently unable to perform their responsibilities and duties normally. Mr. Chen Zhengyong (陳正永), the Vice Chairman and an executive Director of the Company, will temporarily perform Mr. Wu’s responsibilities and duties within the Group, while Mr. Liu Jianzhong (劉建中), the finance director of the Company, will temporarily perform Mr. Chen Peng’s responsibilities and duties within the Group. The Company’s various operating activities remain normal, and based on the current available information, the Board is of the view that this matter has no material adverse impact on the financial position, business or operation of the Group. The Company will make further announcement(s) in accordance with the requirements of relevant laws and regulations and the GEM Listing Rules as and when appropriate.

(2) RE-DESIGNATION OF A DIRECTOR

The Board further announces that Mr. Chen Zhengyong, the Vice Chairman of the Company, has been re-designated from a non-executive Director to an executive Director with effect from 13 December 2024.

The biographical details of Mr. Chen Zhengyong are as follows:

Mr. Chen Zhengyong, aged 61, is the Vice Chairman, an executive Director and the legal representative of the Company. From 1983 to 1993, he was employed at Chengdu Tenth Hospital* (成都市第十醫院) where he was responsible for diagnostic testing. Since 1994, he has been engaged in the business of precision medicine and in vitro diagnostic. He has served as the chairman of the board of a number of companies including Sichuan Zhongsheng Medical Instrument Co., Ltd.* (四川中生醫療器械有限責任公司) (“**Sichuan Zhongsheng**”) since 2012, Sichuan Century Tongchang Health Management Co., Ltd.* (四川世紀同昌健康管理有限責任公司) since 2015 and Chengdu Tongchang Medical Laboratory Co., Ltd.* (成都同昌醫學檢驗所有限公司) since 2017. Mr. Chen Zhengyong obtained his diploma from Chongqing Medical and Pharmaceutical College (重慶醫藥高等專科學校) in clinical laboratory (檢驗專業) in 1983. He studied Chinese language and literature (漢語言文學專業) at Sichuan Broadcast Television University* (四川省廣播電視大學) (currently known as Sichuan Open University (四川開放大學)) from 1985 to 1988, studied Business Administration at Southwestern University of Finance and Economics (西南財經大學) from 2014 to 2016 and studied Business Administration at Peking University (北京大學) from 2018 to 2020. Mr. Chen Zhengyong joined the Company in May 2023.

Mr. Chen Zhengyong’s term of service with the Company will end at the expiration of the term of the current session of the Board. Mr. Chen Zhengyong does not receive any remuneration from the Company. His future remuneration shall be determined by the Board and the remuneration committee with reference to his duties and responsibilities, the performance of the Group and the prevailing market conditions.

Save as disclosed above, Mr. Chen Zhengyong has not held any directorship in any public companies where the securities of which are listed on any securities markets in Hong Kong or overseas in the last three years, nor has he held any other positions with the Company or other members of the Group or had other major appointments or professional qualifications.

As at the date of this announcement, Sichuan Zhongsheng holds 10,000,000 domestic shares of the Company. As Mr. Chen Zhengyong owns 77.94% of equity interests in Sichuan Zhongsheng, he is deemed to be interested in the 10,000,000 domestic shares of the Company owned by Sichuan Zhongsheng under the SFO. Save as disclosed above, he does not have, and is not deemed to have any interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations (as defined in the GEM Listing Rules) which are required to be disclosed pursuant to Part XV of the SFO.

As at the date of this announcement, save as disclosed above, Mr. Chen Zhengyong does not have any relationship with the Directors, senior management, substantial or controlling shareholders (as defined in the GEM Listing Rules) of the Company.

Save as disclosed above, there are no other matters relating to the re-designation of Mr. Chen Zhengyong that should be disclosed pursuant to Rule 17.50(2) of the GEM Listing Rules and there are no other matters that need to be brought to the attention of the shareholders of the Company.

* *For identification purpose only*

For and on behalf of the Board
Biosino Bio-Technology and Science Incorporation
Chen Zhengyong
Vice Chairman and Executive Director

Beijing, the PRC, 13 December 2024

As at the date of this announcement, the Board comprises:

Chairman and executive Director

Mr. Wu Lebin (吳樂斌先生)

Vice chairmen and executive Director

Mr. Chen Zhengyong (陳正永先生)

Vice chairmen and non-executive Director

Mr. Yang Peng (楊鵬先生)

President and executive Director

Mr. Chen Peng (陳鵬先生)

Non-executive Directors

Mr. Li Zhonghua (李忠華先生) and Dr. Gao Guangxia (高光俠博士)

Independent non-executive Directors

Prof. Shen Zuojun (沈佐君教授), Mr. Lu Qi (陸琪先生), Prof. Shen Jiangang (沈劍剛教授) and Dr. He Xin (何欣博士)

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, (1) the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and (2) there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the website of the Stock Exchange at www.hkexnews.hk for at least 7 days from the date of its posting and on the website of the Company at www.zhongsheng.com.cn.